Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutics for preterm labor management

a technology for preterm labor and treatment, applied in the field of biological and medical science, can solve the problems of perinatal morbidity and mortality affecting 12, premature newborns are at increased risk for acute and chronic health problems, developmental deficiencies, marginal efficacy and potential adverse effects on the fetus

Active Publication Date: 2018-12-20
BOARD OF RGT THE UNIV OF TEXAS SYST +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text discusses the need for a safer and more effective tocolytic medication to treat pregnancy-related issues such as premature labor. The current medication, indomethacin, can have harmful effects on the baby, so a targeted approach is needed to make the medication work better and safer for both mother and baby.

Problems solved by technology

Prematurity is a leading cause of perinatal morbidity and mortality affecting 12% of approximately 4 million deliveries in the United States (US).
Premature newborns are at increased risk for both acute and chronic health problems, and developmental deficiencies.
The fundamental problems with tocolytic therapies are their marginal efficacy and potential adverse effects to the fetus.
Unfortunately, although highly demanded, there has been no significant improvement in tocolytic therapies for the past three decades, which can be ascribed to scant innovation in the field of drug therapies for preterm labor.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutics for preterm labor management
  • Therapeutics for preterm labor management
  • Therapeutics for preterm labor management

Examples

Experimental program
Comparison scheme
Effect test

example 1

Liposome (lip) Prevents the Transfer of Indomethacin Across the Placenta to the Fetus

[0051]To determine whether liposomes (LIP) could prevent the transfer of indomethacin (IND) across the placenta to the fetus while preserving its pharmacological activity, multi-lamellar LIP were designed with a 150-200 nm size, fluorescently labeled and loaded with IND (LIP-IND). Characterizations of the liposomes by DLS and SEM showed that the nanoparticles appear as uniform, spherical vesicles of ˜150-170 diameter (FIG. 1). When the size distribution of five separately prepared batches of IND and LIP-IND was evaluated, the average values were 159.8±1.1 nm (polydispersity index, PDI<0.083) for LIP and 164.4±4.7 (PDI: 0.069) for LIP-IND. The low PDI (<0.1) values point towards the homogeneity of the formed phospholipid nanovesicles. Quantitative analysis of the drug revealed that IND encapsulation efficiency in the liposomes was 93%. To enable the biodistribution in the tissues analysis, LIP and IN...

example 2

Targeted Delivery of LIP-IND to the Pregnant Uterus

[0056]Liposome design and fabrication. To achieve active targeting of the LIP-IND system to the uterus, a new method was developed, which involved conjugating clinically used ORA to the liposome's surface. Liposomes loaded with IND and decorated with a clinically available oxytocin receptor antagonist (Flenady et al., 2014) (ORA) on its surface were fabricated into LIP-IND-ORA, as schematically presented in FIG. 5. Oxytocin receptors are specifically expressed on the pregnant uterus. Accordingly, the LIP-IND-ORA were evaluated to determine their ability to specifically direct the delivery of IND to the pregnant uterus, inhibit uterine contractions, and reduce preterm birth.

[0057]For this purpose, the liposomes were engineered to include phospholipids with a spacer and carboxylic group (PEG-DSPE), which can react with the amino group of the ORA using a post-insertion technique. Various concentrations of the constituents were tested. ...

example 3

Materials and Methods

[0067]Liposome design and fabrication. LIP, LIP-IND, LIP-ORA and LIP-IND-ORA were prepared by lipid hydration-extrusion method. First, the lipids were dissolved in 3 mL ethanol at the following concentrations: 9.6-12.2 mg soy bean phosphatidylcholine (Lipoid 5100, Lipoid, Germany), 0-0.77 mg cholesterol (Sigma) and 1-3 mg DSPE-PEG(2000) Carboxylic Acid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (ammonium salt)) (Avanti, Alabama, USA). To fluorescently label LIP, fluorescent phospholipid Lissamine rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt (rhodamine-DHPE, Invitrogen), 2% of the total lipid was incorporated to all liposome formulations. 0.45 mg of IND (Sigma) was added to the above ethanolic mixture for LIP-IND and LIP-IND-ORA formulations. A thin film was formed by evaporating the solvent for 30 minutes (min), 41° C. at 150 rpm using rotary evaporator (Rotavapor, Buchi, Switz...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Methods and compositions are provided for treating and preventing preterm labor using liposome encapsulated tocolytic agents, such as indomethacin. In certain aspects, targeted liposomes are provided that allow delivery of tocolytic agents directly to the uterus, such as by targeting to the oxytocin receptor.

Description

[0001]The present application claims the priority benefit of U.S. provisional application No. 62 / 269,651, filed Dec. 18, 2015, the entire contents of which are incorporated herein by reference.[0002]The invention was made with government support under Grant No: R21 HD082947 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION1. Field of the Invention[0003]The present invention relates generally to the fields of biology and medicine. More particularly, it concerns compositions and methods for preterm labor management.2. Description of Related Art[0004]Prematurity is a leading cause of perinatal morbidity and mortality affecting 12% of approximately 4 million deliveries in the United States (US). Though the etiology of preterm labor is largely unknown, it is defined as regular contractions of the uterus resulting in changes in the cervix prior to 37 weeks of pregnancy. Premature newborns are at increased risk for ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/405A61K38/11A61K9/127A61K47/69A61P15/00A61K38/095
CPCA61K31/405A61K38/11A61K9/1271A61K47/6911A61P15/00A61K9/0019A61K9/127C07K7/16A61K47/62A61P15/06A61K38/095
Inventor REFUERZO, JERRIE S.GODIN, BIANALONGO, MONICA
Owner BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com